That data point toward the video end os worth noting -- ( 2.4% of all Tcells found in the blood were the therapy's engineered Tcells). This data point was very consistent with the % presence as expressed by Dr. Deninger within the findings of the first two patients. He was quite pleased with that initial measurement. This is the potential of "the living drug."

I first heard that "living drug" descriptive as an expression by Dr. Carl June at a celebration video of one of his early CAR-T patients who had reached a ten-year survival.

As an aside, that video gave me information about just how many doses of IL-2 (at a rate of every two hours) could be administered.

In the follow-on video (and this is where our advocate to the media needs to bone up on the landscape and nail the attributes of SB within TCR-T), the question was asked about limitations as to where this TCR-T therapy is going. The gist of the response was: "personalized" is required in solid cancers and affordability is critical.

I hope that most here understand that Sleeping Beauty is the keystone ... "personalized AND affordable" ... a more-than-viable prospect (and the reason to own). There is no doubt in my amateur mind that we are in this trial because Dr. Cooper collaborated with Dr. Rosenberg. Further, Dr. Deniger worked for seven years at NCI (and also noteworthy, Drew was mentored by Cooper in his doctorate). Drew became the agent of providing the game-changing evidence of SB potential, of putting SB into the NCI CRADA. Thanks for posting. All the best.